
Greg Bisconti specializes exclusively in representing life science clients, focusing on tenant representation for the complex needs of small start-ups, fast growth companies, and large pharma clients. He has been personally involved in over 12 million square feet of lease and/or sale transactions, valued at over $4B in consideration, including cGMP manufacturing assignments and other special purpose facilities. Starting with C&W in 1994, Greg has enjoyed a 20+ year career with Cushman & Wakefield and is a leader of its National Life Sciences Advisory Group. His clients have included Dexcom, Biogen Idec, Takeda, Synthetic Genomics, Inception Sciences, UCSD, BASF, Genomatica, Pfizer, Eli Lilly, Alexandria Real Estate Equities, Illumina, and a variety of cutting edge start-ups, such as Quanticel, Metacrine, Organovo, and Ideaya, to name a few. Greg started at Cushman & Wakefield’s San Francisco office in 1994 as a financial analyst and later moved on to leasing and sales, ultimately focusing on tenant representation. He received his Bachelor of Science in Business Administration with a concentration in Real Estate and Urban Land Use from California State University, Sacramento.